




DRUG DISCOVERY

The Future of RNAi Therapeutics

Drug Pipelines and Prospects

By Biophoenix

 **Table of Contents**

Biophoenix

Biophoenix is a biomedical consultancy based in the heart of England, UK, which was founded by Dr Sreten Bogdanovic and Dr Beata Langlands. Established with support from the UK Department of Trade and Industry (DTI) in 1994, Biophoenix provides detailed, accurate, market and technical information to support decision-making by biotechnology-based enterprises in the healthcare industry. In doing so, Biophoenix relies on its comprehensive in-house bioindustry database and a wide network of contacts. Biophoenix also audits biotechnology-based enterprises with regard to the risk of intellectual property litigation on behalf of several Lloyds of London insurers. Further information is available on the internet at www.biophoenix.com.

Dr Bogdanovic is Managing Partner in Biophoenix. He holds a PhD in endocrinology from Imperial College, UK, and has worked as a product manager for immunodiagnostics with the UK subsidiary of Boehringer Mannheim (now owned by Roche), and as an independent biomedical market analyst with Cistrion, UK. Dr Langlands holds a PhD in biochemistry from the University of Glasgow, UK, and has worked as an immunologist, a project leader with a new biotechnology company based at Warwick University in the UK, and as a university lecturer. Biophoenix has researched and written over 50 in-depth management/market reports

Copyright © 2008 Business Insights Ltd

This Management Report is published by Business Insights Ltd. All rights reserved. Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

Table of Contents

RNAi Therapeutics: Drug pipelines and prospects

Executive Summary	14	
RNAi in Infectious Disease	15	
RNAi in Cancer	16	
RNAi in Inflammatory and Other Diseases	18	
RNAi Companies: Technologies and Therapies	19	
Market Trends and Opportunities	19	
Chapter 1	Introduction	24
Summary		24
Introduction		25
Antisense technology		35
Antisense oligonucleotides		35
Ribozymes and DNAzymes		37
Discovery of natural RNAi activated by dsRNA		37
Mechanisms of RNAi stimulated by dsRNA		38
Approaches to activate RNAi in mammals		39
Discovery of micro-RNAs		40
The potential for RNAi-based therapeutics		41
The promise of siRNA therapeutics		41
The promise of miRNAs therapeutics		43
Optimizing siRNA design		44
On- and off-target activity		44
Immune system reactivity		46
Improving siRNA stability		47
Optimizing siRNA delivery		48
Naked siRNA		49
Liposomes and lipoplexes		50
Polymer carriers/nanoparticles		51
Conjugates		52
Optimizing shRNA delivery		53

Chapter 2 RNAi in infectious diseases 56

Summary	56
Introduction	57
Respiratory viral infections	58
RSV virus	60
Clinical and biological features	60
Design of RNAi therapeutics	62
RNAi therapeutics in development	63
Influenza virus	64
Clinical and biological features	65
Design of RNAi therapeutics	68
RNAi therapeutics in development	69
SARS	70
RNAi therapeutics in development	71
Chronic viral infections	71
Hepatitis viruses	71
Clinical and biological features	71
Design of RNAi therapeutics	73
RNAi drugs in development	74
HIV virus	77
Clinical and biological features	77
Design of RNAi therapeutics	80
RNAi drugs in development	82
HPV	83
HSV	83
Viral hemorrhagic fever and Ebola	84
Malaria	85

Chapter 3 RNAi in Cancer 88

Summary	88
Introduction	89
Cancer types	91
Treatment of cancer	94
Approaches to RNAi in cancer therapy	96
Approaches to RNAi delivery	99
Targeting microRNAs	100
RNAi cancer therapeutics in development	100
Agents directed at established targets	100
Agents directed at novel targets	102
Agents directed at multiple targets	104
Agents directed at unspecified targets	105

microRNAs	105
DNAi therapeutics	105

Chapter 4 RNAi in inflammatory and other diseases 108

Summary	108
Introduction	109
Inflammation/immune dysfunction	109
Current therapies	112
Allergies and respiratory diseases	114
RNAi therapeutics in development	116
Age-related macular degeneration	118
RNAi therapeutics in development	120
Other inflammatory conditions	122
RNAi therapeutics in development	123
Acute Renal Failure	123
RNAi therapeutics in development	124
CNS diseases	125
Huntington's disease	125
RNAi therapeutics in development	125
Parkinson's disease	126
RNAi therapeutics in development	126
Other CNS conditions	127
Cardiology and metabolism	129
Cardiovascular disease	129
RNAi agents in development	130
Type 2 diabetes	132
RNAi agents in development	132
Non-alcoholic steatohepatitis	133
Other indications	133

Chapter 5 RNAi Companies: Technologies and Therapies 138

Summary	138
Alnylam Pharmaceuticals Inc	139
Company description	139
RNAi-related technology	139
Candidate RNAi therapeutics	141
RNAi-related agreements	142
Ambrilia Biopharma Inc	145
Company description	145

RNAi-related technology	146
Candidate RNAi therapeutics	146
Angioblast Systems Inc	146
Company description	146
RNAi-related technology	146
Candidate RNAi therapeutics	146
AVI BioPharma Inc	147
Company description	147
Exon Skipping Pre-RNA Interference Technology (ESPRIT)	148
RNA splicing-related agreements	148
Benitec Ltd	149
Company description	149
RNAi-related technology	149
Candidate RNAi therapeutics	150
RNAi-related agreements	150
BioCancell Therapeutics Inc	151
Company description	151
Candidate RNAi therapeutics	152
RNAi-related agreements	152
Calando Pharmaceuticals Inc	152
Company description	152
RNAi-related technology	153
Candidate RNAi therapeutics	153
RNAi-related agreements	153
Cequent Pharmaceuticals Inc	154
Company description	154
RNAi-related technology	154
Candidate RNAi therapeutics	154
Dicerna Pharmaceuticals Inc	154
Company description	154
RNAi-related technology	155
Candidate RNAi therapeutics	155
Generex Biotechnology Corp	155
Company description	156
RNAi-related technology	156
Candidate RNAi therapeutics	156
RNAi-related agreements	156
Genesis Research and Development Corp	157
Company description	157
RNAi-related technology	157
Candidate RNAi therapeutics	158
Green Cross Corp	158
Company description	158
Candidate RNAi therapeutics	158
Gruenthal Group	159
Company description	159
RNAi-related technology	159

Candidate RNAi therapeutics	159
Intradigm Corp	159
Company description	159
RNAi-related technology	159
Candidate RNAi therapeutics	160
RNAi-related agreements	160
Isis Pharmaceuticals Inc	161
Company description	161
RNAi-related agreements	162
Lorus Therapeutics Inc	163
Company description	163
Candidate RNAi therapeutics	163
MDRNA Inc	164
Company description	164
RNAi-related technology	164
Candidate RNAi therapeutics	165
RNAi-related agreements	165
Merck & Co Inc	165
Company description	165
RNAi-related technology	166
Candidate RNAi therapeutics	166
RNAi-related agreements	167
Nucleonics Inc	168
Company description	168
RNAi-related technology	168
Candidate RNAi therapeutics	169
RNAi-related agreements	169
Opko Health Inc	169
Company description	169
Candidate RNAi therapeutics	170
RNAi-related agreements	170
ProNAi Therapeutics Inc	170
Company description	170
RNAi-related technology	171
Candidate DNAi therapeutics	171
DNAi-related agreements	171
Quark Pharmaceuticals Inc	172
Company description	172
RNAi-related technology	172
Candidate RNAi therapeutics	172
RNAi-related agreements	172
Regulus Therapeutics LLC	173
Company description	173
miRNA-related technology	173
Candidate miRNA therapeutics	174
RNAi-related agreements	174
Rosetta Genomics Ltd	175

Company description	175
miRNA-related technology	175
Candidate miRNA therapeutics	175
miRNA-related agreements	176
RXi Pharmaceuticals Corp	176
Company description	176
RNAi-related technology	177
Candidate RNAi therapeutics	177
RNAi-related agreements	177
Santaris Pharma A/S	178
Company description	178
RNAi-related technology	178
Candidate miRNA therapeutics	179
RNAi-related agreements	179
Senesco Technologies Inc	180
Company description	180
Candidate RNAi therapeutics	180
Senetek plc	181
Company description	181
Candidate RNAi therapeutics	181
RNAi-related agreements	181
Silence Therapeutics plc	182
Company description	182
RNAi-related technology	182
Candidate RNAi therapeutics	183
RNAi-related agreements	183
Sirnaomics Inc	184
Company description	184
RNAi-related technology	184
Candidate RNAi therapeutics	184
RNAi-related agreements	184
siRNAsense AS	185
Company description	185
Candidate RNAi therapeutics	185
RNAi-related agreements	185
Stelic Institute & Co	186
Company description	186
Candidate RNAi therapeutics	186
RNAi-related agreements	186
Targeted Genetics Corp	187
Company description	187
RNAi-related technology	187
Candidate RNAi therapeutics	188
RNAi-related agreements	188
Tekmira Pharmaceuticals Corp	188
Company description	188
RNAi-related technology	189
Candidate RNAi therapeutics	189

RNAi-related agreements	189
ToleroTech Inc	190
Company description	190
RNAi-related technology	190
Candidate RNAi therapeutics	191
Topigen Pharmaceuticals Inc	191
Company description	191
RNAi-related technology	191
Candidate RNAi therapeutics	192
TransDerm Inc	192
Company description	192
RNAi-related technology	192
Candidate RNAi therapeutics	193

Chapter 6 Market trends and opportunities 196

Summary	196
Validating RNAi in the clinic	197
From first-in-class to best-in-class	199
Exploring alternatives to siRNAs	200
Overcoming delivery challenges	201
Moving beyond "druggable" targets	202
Intellectual property considerations	207
Introduction to RNAi patents	207
Fire and Mello Patent	208
Tuschl Patents	208
Kreutzer-Limmer Patents	210
Benitec patents	210
Crooke / RNAi modification patents	212
Glover patent	213
RNAi target patents	213
miRNA patents	214
Effect of patents on infringing R&D	214
Patent survey results	214
Market value considerations	225
Commercial prospects	225
Summary of key indications	226
Forecasts	226
Wet AMD: bevasiranib and others	226
RSV infection: ALN-RSV01	228
Acute renal failure: AKTi-5	228
The RNAi bottom line	229
Company details	232
Alnylam Pharmaceuticals Inc	232

Ambrilia Biopharma Inc	232
Angioblast Systems Inc	233
AVI BioPharma Inc	233
Benitec Ltd	234
BioCancell Therapeutics Inc	234
Calando Pharmaceuticals Inc	235
Cequent Pharmaceuticals Inc	235
Dicerna Pharmaceuticals Inc	236
Generex Biotechnology Corp	236
Genesis Research and Development Corp	237
Green Cross Corp	237
Gruenenthal Group	238
Intradigm Corp	238
Isis Pharmaceuticals Inc	238
Lorus Therapeutics Inc	239
MDRNA Inc	239
Merck & Co Inc	240
Nucleonics Inc	240
Opko Health Inc	241
ProNAi Therapeutics Inc	241
Quark Pharmaceuticals Inc	242
Regulus Therapeutics LLC	242
Rosetta Genomics Ltd	242
RXi Pharmaceuticals Corp	243
Santaris Pharma A/S	243
Senesco Technologies Inc	244
Senetek plc	244
Silence Therapeutics plc	245
Sirnaomics Inc	245
siRNAsense AS	246
Stelic Institute & Co	246
Targeted Genetics Corp	246
Tekmira Pharmaceuticals Corp	247
ToleroTech Inc	247
Topigen Pharmaceuticals Inc	248
TransDerm Inc	248

Glossary	249
Abbreviations and acronyms	249

List of Figures

Figure 6.1:	RNAi by development stage	197
Figure 6.2:	RNAi by origin of material	203
Figure 6.3:	RNAi USPTO patents: therapy area	222
Figure 6.4:	RNAi WIPO patents: therapy area	223
Figure 6.5:	RNAi USPTO Patents: patent focus	224
Figure 6.6:	RNAi WIPO patents: patent focus	225

List of Tables

Table 1.1:	RNAi Oligonucleotide Indications – Infectious Disease	27
Table 1.2:	RNAi Oligonucleotide Indications – Cancer	28
Table 1.3:	RNAi Oligonucleotide Indications – Cancer (continued)	29
Table 1.4:	RNAi Oligonucleotide Indications – Cancer (continued)	30
Table 1.5:	RNAi Oligonucleotide Indications – Miscellaneous Disorders	30
Table 1.6:	RNAi Oligonucleotide Indications – CNS	31
Table 1.7:	RNAi Oligonucleotide Indications – Inflammation/Immune Disorders	32
Table 1.8:	RNAi Oligonucleotide Indications – Inflammation/Immune Disorders (continued)	33
Table 1.9:	RNAi Oligonucleotide Indications – Cardiology, Metabolism	34
Table 5.10:	Financial Details, year ending Dec 2007, (US\$m): Alnylam Pharmaceuticals Inc	139
Table 5.11:	Financial Details, year ending 2007, (Can\$m): Ambrilia Biopharma Inc	145
Table 5.12:	Financial Details, year ending Dec 2007, (US\$m): AVI BioPharma Inc	147
Table 5.13:	Financial Details, year ending Jun 2007, (Aus\$m): Benitec Ltd	149
Table 5.14:	Financial Details, year ending Dec 2006, (NIS\$m): BioCancell Therapeutics Inc	151
Table 5.15:	Financial Details, year ending July 2007, (US\$m): Genex Biotechnology Corp	155
Table 5.16:	Financial Details, year ending Dec 2007, (NZ\$m): Genesis Research and Development Corp	157
Table 5.17:	Financial Details, year ending Dec 2006, (W\$m): Green Cross Corp	158
Table 5.18:	Financial Details, year ending Dec 2007, (US\$m): Isis Pharmaceuticals Inc	161
Table 5.19:	Financial Details, year ending May 2007, (Can\$m): Lorus Therapeutics Inc	163
Table 5.20:	Financial Details, year ending Dec 2007, (US\$m): MDRNA Inc	164
Table 5.21:	Financial Details, year ending Dec 2007, (US\$m): Merck & Co Inc	165
Table 5.22:	Financial Details, year ending Dec 2007, (US\$m): Opko Health Inc	169
Table 5.23:	Financial details, year ending Dec 2007, (US\$m): Rosetta Genomics Ltd	175
Table 5.24:	Financial details, year ending Dec 2007, (US\$m):RXi Pharmaceuticals Corp	176
Table 5.25:	Financial details, year ending Jun 2007, (US\$m): Senesco Technologies Inc	180
Table 5.26:	Financial details, year ending Dec 2007, (US\$m): Senetek plc	181
Table 5.27:	Financial details, year ending Dec 2007, (£m): Silence Therapeutics plc	182
Table 5.28:	Financial details, year ending Dec 2007, (US\$m): Targeted Genetics Corp	187
Table 5.29:	Financial details, year ending Dec 2007, (Can\$m): Tekmira Pharmaceuticals Corp	188
Table 6.30:	Common RNAi/Antisense Targets	204
Table 6.31:	Common RNAi/Antisense Targets (Contd.)	205
Table 6.32:	Targets of Antisense Oligonucleotides but not RNAis	206
Table 6.33:	WIPO RNAi Patents: Filing and Publication Dates	215
Table 6.34:	USPTO RNAi Patents: Filing and Publication Dates	215
Table 6.35:	WIPO RNAi Patents: Top Assignees	217
Table 6.36:	WIPO RNAi Patents: Top Assignees (Contd.)	218
Table 6.37:	WIPO RNAi Patents: Top Assignees (Contd.)	219
Table 6.38:	USPTO RNAi Patents: Top Assignees	220
Table 6.39:	Leading RNAi Oligonucleotide Originators	221
Table 6.40:	Key data: Forecasts for wet AMD, RSV therapy and acute renal failure (\$m), 2012	229

